Neurent Medical, developing a new treatment for chronic rhinitis, also enters strategic partnership with Northwell Health. Irish lifesciences and health tech companies Shorla Oncology, FIRE1, Head Diagnostics, and X-Bolt announce U.S. expansion.
Northwell Health, one of the largest and most respected health systems in the United States, today signed a new strategic alliance with Enterprise Ireland, the government of Ireland’s trade and innovation agency and the world’s most active life sciences and health tech investor by deal count. This new alliance builds on a successful relationship that has been a cornerstone of Irish health tech and medtech expansion into the U.S. market since 2016 and sets a new ambition to further accelerate the commercialisation and scaling of Irish lifesciences and health tech companies in the United States.
The signing took place today in New York, witnessed by Ireland’s Minister for Enterprise, Tourism and Employment, Peter Burke; Elaine Brennan, Executive Director of Global Strategic Partnerships at Northwell Health; and Kevin Sherry, Executive Director at Enterprise Ireland.
Northwell Health is currently engaged with 18 Enterprise Ireland lifesciences and health tech companies. The alliance has delivered tangible, measurable outcomes for these companies, including procurement contracts with Northwell Health, clinical pilots and trials, and strategic investments through Northwell Ventures.
Today, Northwell Health also signed a partnership with Galway-based MedTech company Neurent Medical, whose NEUROMARK technology, developed with early support from Enterprise Ireland, has benefited from Northwell’s clinical network as the company scales across the U.S. market. Neurent Medical recently closed an oversubscribed €62.5 million ($74 million) Series C funding round and is developing innovative, minimally invasive treatments for chronic rhinitis and other chronic inflammatory sinonasal diseases.
Minister for Enterprise, Tourism and Employment, Peter Burke said:
“Northwell Health has been an invaluable partner to Ireland and to Irish health tech and medtech companies. This alliance has provided Irish companies with unparalleled opportunities and privileged access to Northwell Health’s vast clinical network, serving as a critical gateway for innovative Irish companies entering and scaling within the U.S. healthcare market. Ireland’s life sciences and health tech sector is thriving, and partnerships like this are central to ensuring that innovation emerging from Ireland reaches patients in the U.S. and around the world.”
Elaine Brennan, Executive Director, Global Strategic Partnerships, Northwell Health, said:
“Northwell Health is proud to sign this new strategic alliance with Enterprise Ireland and build upon years of successful collaboration. Our International Business Program has proven to be an invaluable gateway for innovative international companies seeking to enter and scale within the U.S. healthcare market. Since 2016, we have provided Enterprise Ireland client companies with direct access to clinical experts across one of America’s largest health systems, resulting in meaningful outcomes including procurement contracts, clinical pilots and trials, and strategic investments from Northwell Ventures. We look forward to welcoming the next generation of Irish healthcare innovators and supporting their growth in the U.S. market.”
Kevin Sherry, Executive Director, Enterprise Ireland, said:
“Ireland’s life sciences and health tech sector is producing world-class innovation at a remarkable pace and is attracting record VC investment, a testament to the depth and quality of Ireland’s R&D ecosystem. Our new strategic alliance with Northwell Health sits at the heart of that ambition, providing significant opportunities for innovative Irish companies to commercialise and co-develop new innovations and enter the U.S. market. The partnership between Neurent Medical and Northwell Health is a great example of the excellent collaboration that exists between Ireland and the United States across the healthcare industry.”
Under the new agreement, Enterprise Ireland client companies will continue to benefit from direct access to Northwell’s leading clinical experts across its network of 28 hospitals and more than 1,000 outpatient facilities, as well as introductions to Northwell’s innovation and commercial infrastructure.
This new alliance reflects Ireland’s emergence as a global hub in lifesciences and health technology innovation and investment. In 2024, according to PitchBook data, Ireland recorded €491 million in lifesciences and healthtech VC investment, underscoring the strength of the Irish innovation ecosystem.
Enterprise Ireland’s support for Irish lifesciences and health tech companies goes beyond capital. By forging deep institutional relationships with leading U.S. health systems such as Northwell Health, Enterprise Ireland equips client companies with the clinical access, commercial expertise, and market credibility needed to succeed in the highly competitive U.S. market.
Neurent Medical – Strategic Partnership with Northwell Health
Neurent Medical develops innovative, minimally invasive treatments for chronic inflammatory sinonasal diseases, with a particular focus on chronic rhinitis. The company’s proprietary NEUROMARK technology enables ENT physicians to precisely target and disrupt overactive autonomic nerves to reduce rhinitis symptoms through an in-office procedure, offering patients a clinically effective alternative to ongoing medication. Neurent Medical has a U.S. headquarters in Braintree, Massachusetts, supporting its commercialisation and clinical engagement in the U.S. market.
Enterprise Ireland has supported Neurent Medical since its early stages, providing a commercialisation grant that enabled the company’s foundational development and subsequently participating in its Series A financing round. The Northwell Health partnership is pivotal in Neurent Medical’s U.S. market development, providing the validation and institutional relationships central to scaling a medtech innovation in the U.S. healthcare system.
In February 2026, Neurent Medical closed an oversubscribed Series C funding round raising €62.5 million (approximately $74 million). The round was led by MVM Partners with participation from Sofinnova Partners and continued support from existing investors including EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland.
Irish Lifesciences and Health Tech Companies Expanding in the U.S.
This week, several leading Irish lifesciences and health tech companies announced expansion in the United States:
- Shorla Oncology, founded by Sharon Cunningham and Orlaith Ryan, is a commercial-stage specialty pharmaceutical company with four FDA-approved products. The company has expanded its U.S. commercial infrastructure, establishing a field team of Oncology Key Account Managers to support outreach for its oral liquid oncology products, IMKELDI® and JYLAMVO®. Offices are located in Tipperary, Ireland and Cambridge, Massachusetts.
- FIRE1, led by Conor Hanley, has opened its first U.S. office in Cambridge, Massachusetts, as it prepares for its pivotal NORM-HF clinical study and future commercialization. FIRE1 develops technology to improve heart failure management through physician-directed patient self-monitoring. The company raised $120 million in January 2025.
- Head Diagnostics has announced two new U.S. clinical partnerships with neurological centers, including one of the largest outpatient neurology practices in the United States. The company develops digital neuroclinical support solutions to identify cognitive decline early and will deploy its HDx Cognition platform across clinical environments.
- X-Bolt, headquartered in Dublin, has partnered with Vizient, a leading U.S. healthcare performance improvement company. Its patented expanding bolt technology improves fixation for bone fractures. This partnership will expand access across Vizient’s network of over 5,000 hospitals.
About Enterprise Ireland
Enterprise Ireland is the Irish government organization responsible for the development and growth of Irish enterprises in global markets. It works in partnership with Irish companies to help them start, grow, innovate, and win export sales worldwide.
In 2024, PitchBook named Enterprise Ireland as the world’s most active lifesciences and healthtech venture capital investor, participating in 60 deals as Ireland recorded €491 million in lifesciences and healthtech investment.
About Northwell Health
Northwell is the largest not-for-profit health system in the Northeast, serving residents of New York and Connecticut with 28 hospitals, more than 1,000 outpatient facilities, 22,000 nurses, and over 20,000 physicians.
Northwell cares for more than three million people annually across the New York metro area, including Long Island, the Hudson Valley, western Connecticut, and beyond, supported by community philanthropy. It is New York State’s largest private employer, with more than 104,000 employees—including members of Northwell Health Physician Partners and Nuvance Health Medical Practices—working to transform healthcare.
Named one of TIME100’s Most Influential Companies in 2025, Northwell is advancing breakthroughs through the Feinstein Institutes for Medical Research and training future medical professionals at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies.
For more information on its more than 100 medical specialties, visit Northwell.edu or follow @NorthwellHealth on Facebook, X, Instagram, and LinkedIn.
About Neurent Medical
Neurent Medical is a Galway-based MedTech company that develops minimally invasive treatments for chronic inflammatory sinonasal diseases. Its proprietary NEUROMARK technology enables ENT physicians to target overactive autonomic nerves in a simple, in-office procedure.
Founded as a spin-out from NUI Galway and supported by Enterprise Ireland, Neurent Medical maintains U.S. headquarters in Braintree, Massachusetts. In February 2026, the company closed an oversubscribed €62.5 million Series C funding round led by MVM Partners.
The Editorial Team at Healthcare Business Today is made up of experienced healthcare writers and editors, led by managing editor Daniel Casciato, who has over 25 years of experience in healthcare journalism. Since 1998, our team has delivered trusted, high-quality health and wellness content across numerous platforms.
Disclaimer: The content on this site is for general informational purposes only and is not intended as medical, legal, or financial advice. No content published here should be construed as a substitute for professional advice, diagnosis, or treatment. Always consult with a qualified healthcare or legal professional regarding your specific needs.
See our full disclaimer for more details.
